BICD2 is the second human homolog discovered to the  Drosophila Bicaudal-D protein that forms part of the cytoskeleton and mediates the correct sorting of mRNAs for oocyte- and axis-determining factors during oogenesis.  Similar to the highly homologous protein BICD1, BICD2 can bind to dynein-dynactin complex, primarily through the dynamitin subunit of dynactin.  The C-terminus of BICD2 targets the protein to the Golgi complex while the N-terminal domain of BICD2 co-immunoprecipitates with cytoplasmic dynein, suggesting BICD2 plays a role in the dynein-dynactin interaction on the surface of membranous organelles.  Mice engineered to overexpress the BICD2 amino terminal domain in neurons developed amyotrophic lateral sclerosis (ALS)-like features such as Golgi fragmentation, neurofilament swelling in proximal axons, etc., suggesting that impaired dynein/dynactin function may explain some of the pathological features observed in ALS patients.  This BICD2 antibody will not cross-react with BICD1.